NCT02955082 2026-02-04
BARCODE2
Institute of Cancer Research, United Kingdom
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT00667199 2023-04-19
BAY88-8223, Does Response Study in HRPC Patients
Bayer
Phase 2 Completed
NCT01741116 2021-02-18
Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer
Korean Cancer Study Group
Phase 2 Completed
NCT00629525 2015-03-03
RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer
Duke University
Phase 2 Completed
NCT00313482 2012-05-11
PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC
Veeda Oncology
Phase 2 Terminated
NCT00525408 2012-03-12
HRPC
Cadila Pharnmaceuticals
Phase 2 Terminated
NCT01215799 2011-12-15
PROACT
CytRx
Phase 2 Completed
NCT00407251 2010-11-05
Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy
British Columbia Cancer Agency
Phase 2 Completed
NCT00795171 2010-08-18
Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer
Medical University of Vienna
Phase 2 Unknown